Chardan initiated coverage of Unity Biotechnology (UBX) with a Buy rating and $6 price target The company’s lead candidate UBX1325 is currently being investigated in the Phase 2b ASPIRE trial in treatment-experienced diabetic macular edema patients, with topline data expected in Q1 of 2025, notes the analyst, who bases the firm’s rating and target on the potential of UBX1325 in DME.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UBX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue